Notably, the combination therapy produced the most significant improvements, with ZO‐1 gene expression increasing by 4.29‐fold (F = 65.2, p < 0.0001) and AMPK content by 3.36‐fold (F = 78.34, p < 0.0001) compared to the colitis group. The gene discussed is TJP1; the disease is colitis.